CN108273523A - 一种抗凝血药物中间体的生产方法 - Google Patents
一种抗凝血药物中间体的生产方法 Download PDFInfo
- Publication number
- CN108273523A CN108273523A CN201810282030.4A CN201810282030A CN108273523A CN 108273523 A CN108273523 A CN 108273523A CN 201810282030 A CN201810282030 A CN 201810282030A CN 108273523 A CN108273523 A CN 108273523A
- Authority
- CN
- China
- Prior art keywords
- catalyst
- pyridine
- hydrogen
- bases
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 230000010100 anticoagulation Effects 0.000 title abstract description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 66
- 238000006243 chemical reaction Methods 0.000 claims abstract description 55
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical class CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000003054 catalyst Substances 0.000 claims abstract description 51
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 51
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims abstract description 40
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract description 33
- ITRNXVSDJBHYNJ-UHFFFAOYSA-N tungsten disulfide Chemical compound S=[W]=S ITRNXVSDJBHYNJ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 17
- 239000011943 nanocatalyst Substances 0.000 claims abstract description 16
- 239000006185 dispersion Substances 0.000 claims abstract description 15
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 43
- 239000002585 base Substances 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 19
- 238000002425 crystallisation Methods 0.000 claims description 18
- 230000008025 crystallization Effects 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- 238000005984 hydrogenation reaction Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000012296 anti-solvent Substances 0.000 claims description 8
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000012018 catalyst precursor Substances 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000012805 post-processing Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- SHWZFQPXYGHRKT-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;nickel Chemical compound [Ni].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O SHWZFQPXYGHRKT-FDGPNNRMSA-N 0.000 claims 2
- 241000549556 Nanos Species 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 abstract description 9
- 229910052759 nickel Inorganic materials 0.000 abstract description 3
- 229960000288 dabigatran etexilate Drugs 0.000 abstract description 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- WNZGJIQDCXHAOS-UHFFFAOYSA-N 2-(methylamino)-3-nitrobenzamide Chemical compound CNc1c(cccc1[N+]([O-])=O)C(N)=O WNZGJIQDCXHAOS-UHFFFAOYSA-N 0.000 abstract 1
- -1 amino, 4 methylamino benzoyl Chemical group 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229960003850 dabigatran Drugs 0.000 description 6
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 6
- BMGNSKKZFQMGDH-FDGPNNRMSA-L nickel(2+);(z)-4-oxopent-2-en-2-olate Chemical compound [Ni+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O BMGNSKKZFQMGDH-FDGPNNRMSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003746 feather Anatomy 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- VEJOYRPGKZZTJW-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;platinum Chemical compound [Pt].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O VEJOYRPGKZZTJW-FDGPNNRMSA-N 0.000 description 2
- RPKCLSMBVQLWIN-UHFFFAOYSA-N 2-n-methylbenzene-1,2-diamine Chemical compound CNC1=CC=CC=C1N RPKCLSMBVQLWIN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 150000002240 furans Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940127066 new oral anticoagluant drug Drugs 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WNOSSDZXZJHRNE-UHFFFAOYSA-N 4-(methylamino)-3-nitrobenzamide Chemical class CNC1=CC=C(C(N)=O)C=C1[N+]([O-])=O WNOSSDZXZJHRNE-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/02—Sulfur, selenium or tellurium; Compounds thereof
- B01J27/04—Sulfides
- B01J27/043—Sulfides with iron group metals or platinum group metals
- B01J27/045—Platinum group metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Description
时间/min | 流动相A(V%) | 流动相B(V%) |
0 | 10 | 90 |
2 | 15 | 85 |
20 | 80 | 20 |
25 | 80 | 20 |
30 | 10 | 90 |
32 | 10 | 90 |
Pt/Ni/W摩尔比 | Pt(acac)2 | Ni(acac)2 | WS2 | 催化剂编号 |
100/0/0 | 100 | 0 | 0 | Cat-Pt |
0/100/0 | 0 | 100 | 0 | Cat-Ni |
90/10/0 | 90 | 10 | 0 | Cat-Pt90/Ni10 |
80/10/10 | 80 | 10 | 10 | Cat-Pt80/Ni10/W10 |
80/20/5 | 80 | 20 | 5 | Cat-Pt80/Ni10/W5 |
序列 | 催化剂 | 反应时间/h | 转化率/% | 选择性/% |
1 | Cat-Pt | 12 | 53.6 | 83.9 |
2 | Cat-Ni | 12 | 39.8 | 92.3 |
3 | Cat-Pt90/Ni10 | 8 | 82.4 | 90.3 |
4 | Cat-Pt80/Ni10/W10 | 6 | 99.6 | 83.2 |
5 | Cat-Pt80/Ni10/W5 | 4 | 98.5 | 93.2 |
溶剂 | 反应时间/h | 催化剂用量/%wt | 压力/MPa | 转化率/% | 选择性/% |
甲醇 | 4 | 10 | 1 | 98.6 | 93.1 |
乙醇 | 5 | 10 | 1 | 96.2 | 92.6 |
异丙醇 | 8 | 10 | 1 | 95.3 | 92.8 |
二氯甲烷 | 24 | 10 | 1 | 32.1 | — |
乙酸乙酯 | 12 | 10 | 1 | 68.3 | 93.6 |
四氢呋喃(THF) | 4 | 10 | 1 | 99.8 | 91.6 |
乙腈 | 8 | 10 | 1 | 91.9 | 92.6 |
DMF | 8 | 10 | 1 | 89.2 | 98.6 |
VTHF/DMF=100:10 | 6 | 10 | 1 | 99.8 | 97.2 |
VTHF/DMF=100:10 | 24 | 10 | 0.1 | 98.2 | 97.3 |
VTHF/DMF=100:10 | 10 | 10 | 0.3 | 98.6 | 97.4 |
VTHF/DMF=100:10 | 8 | 10 | 0.5 | 99.8 | 97.3 |
VTHF/DMF=100:10 | 4 | 10 | 2.0 | 100 | 97.2 |
VTHF/DMF=100:10 | 10 | 5 | 0.5 | 99.6 | 97.2 |
VTHF/DMF=100:10 | 9 | 8 | 0.5 | 99.7 | 97.3 |
套用次数 | 1 | 2 | 3 | 4 | 5 |
转化率/% | 99.8 | 99.2 | 98.9 | 98.1 | 96.1 |
选择性/% | 97.2 | 97.3 | 97.1 | 96.8 | 92.3 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810282030.4A CN108273523B (zh) | 2018-04-02 | 2018-04-02 | 一种抗凝血药物中间体的生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810282030.4A CN108273523B (zh) | 2018-04-02 | 2018-04-02 | 一种抗凝血药物中间体的生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108273523A true CN108273523A (zh) | 2018-07-13 |
CN108273523B CN108273523B (zh) | 2020-09-22 |
Family
ID=62811072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810282030.4A Expired - Fee Related CN108273523B (zh) | 2018-04-02 | 2018-04-02 | 一种抗凝血药物中间体的生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108273523B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114990191A (zh) * | 2022-08-02 | 2022-09-02 | 可孚医疗科技股份有限公司 | 凝血酶定量检测酶试剂的制备方法及凝血酶定量检测卡 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62260031A (ja) * | 1986-05-07 | 1987-11-12 | Tohoku Metal Ind Ltd | 耐摩耗性高透磁率合金 |
CN103242226A (zh) * | 2013-04-22 | 2013-08-14 | 华东师范大学 | 药物中间体3-[(3-氨基-4-甲胺基苯甲酰基)(吡啶-2-基)氨基]丙酸乙酯的制备方法 |
CN104593050A (zh) * | 2013-11-03 | 2015-05-06 | 中国石油化工股份有限公司 | 硫化型加氢催化剂的开工方法 |
US20150266732A1 (en) * | 2012-10-08 | 2015-09-24 | King Abdullah University Of Science And Technology | METHODS TO SYNTHESIZE NiPt BIMETALLIC NANOPARTICLES BY A REVERSED-PHASE MICROEMULSION, DEPOSITION OF NiPt BIMETALLIC NANOPARTICLES ON A SUPPORT, AND APPLICATION OF THE SUPPORTED CATALYST FOR CO2 REFORMING OF METHANE |
CN105968049A (zh) * | 2016-04-08 | 2016-09-28 | 深圳市茵诺圣生物科技有限公司 | 一种制备1-(2,6-二氯苄基-3-(吡咯烷-1-甲基)-6-氨基吲唑的方法 |
CN106582713A (zh) * | 2016-12-13 | 2017-04-26 | 扬州大学 | 一种Pt3Ni@PtNi2核壳结构纳米线的制备方法 |
JP2018107107A (ja) * | 2016-12-27 | 2018-07-05 | ダイハツ工業株式会社 | プロトン交換形燃料電池 |
KR20180109231A (ko) * | 2017-03-27 | 2018-10-08 | 한국과학기술원 | 백금 박막 증착된 팔면체 백금-전이금속 나노입자, 이의 제조방법 및 이를 포함하는 막전극접합체 제조 방법 |
-
2018
- 2018-04-02 CN CN201810282030.4A patent/CN108273523B/zh not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62260031A (ja) * | 1986-05-07 | 1987-11-12 | Tohoku Metal Ind Ltd | 耐摩耗性高透磁率合金 |
US20150266732A1 (en) * | 2012-10-08 | 2015-09-24 | King Abdullah University Of Science And Technology | METHODS TO SYNTHESIZE NiPt BIMETALLIC NANOPARTICLES BY A REVERSED-PHASE MICROEMULSION, DEPOSITION OF NiPt BIMETALLIC NANOPARTICLES ON A SUPPORT, AND APPLICATION OF THE SUPPORTED CATALYST FOR CO2 REFORMING OF METHANE |
CN103242226A (zh) * | 2013-04-22 | 2013-08-14 | 华东师范大学 | 药物中间体3-[(3-氨基-4-甲胺基苯甲酰基)(吡啶-2-基)氨基]丙酸乙酯的制备方法 |
CN104593050A (zh) * | 2013-11-03 | 2015-05-06 | 中国石油化工股份有限公司 | 硫化型加氢催化剂的开工方法 |
CN105968049A (zh) * | 2016-04-08 | 2016-09-28 | 深圳市茵诺圣生物科技有限公司 | 一种制备1-(2,6-二氯苄基-3-(吡咯烷-1-甲基)-6-氨基吲唑的方法 |
CN106582713A (zh) * | 2016-12-13 | 2017-04-26 | 扬州大学 | 一种Pt3Ni@PtNi2核壳结构纳米线的制备方法 |
JP2018107107A (ja) * | 2016-12-27 | 2018-07-05 | ダイハツ工業株式会社 | プロトン交換形燃料電池 |
KR20180109231A (ko) * | 2017-03-27 | 2018-10-08 | 한국과학기술원 | 백금 박막 증착된 팔면체 백금-전이금속 나노입자, 이의 제조방법 및 이를 포함하는 막전극접합체 제조 방법 |
Non-Patent Citations (2)
Title |
---|
MACARENA MUNOZ等: "Size-controlled PtNi nanoparticles as highly efficient catalyst forhydrodechlorination reactions", 《APPLIED CATALYSIS B: ENVIRONMENTAL》 * |
吴佳: "成分调控的PtNi合金纳米粒子形貌演化及燃料电池电催化活性研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114990191A (zh) * | 2022-08-02 | 2022-09-02 | 可孚医疗科技股份有限公司 | 凝血酶定量检测酶试剂的制备方法及凝血酶定量检测卡 |
CN114990191B (zh) * | 2022-08-02 | 2022-10-18 | 可孚医疗科技股份有限公司 | 凝血酶定量检测酶试剂的制备方法及凝血酶定量检测卡 |
Also Published As
Publication number | Publication date |
---|---|
CN108273523B (zh) | 2020-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3805196B1 (en) | Preparation method for high optical indoxacarb intermediate | |
CN101492380B (zh) | 米格列醇关键中间体的制备方法 | |
CN108273523A (zh) | 一种抗凝血药物中间体的生产方法 | |
CN101628909B (zh) | 用乙二醇合成1,4-二氧六环-2-酮的方法 | |
CN101239923B (zh) | (s,s)n-(1-乙氧羰基-3-苯丙基)-l-氨基酸衍生物的制备方法与精制方法 | |
CN107987028B (zh) | 一种治疗ⅱ型糖尿病药物中间体的制备方法 | |
CN102180811B (zh) | 一种氯氰碘柳胺钠中间体的催化加氢制备方法 | |
CN107597157B (zh) | 一种用于制备抗肿瘤药物中间体的固体酸催化剂及其制备方法 | |
CN114605274B (zh) | 一种加氢法合成邻氨基苯甲醚的生产工艺 | |
CN115651048A (zh) | 一种普罗雌烯的合成工艺及其应用 | |
CN109824634A (zh) | 一种糠醛直接氧化酯化制备糠酸甲酯的方法 | |
CN114522737A (zh) | 一种高选择性制备3-乙酰氧基丙醇的方法 | |
CN107185571B (zh) | 钴催化剂及其制备方法和在催化合成2,3,5-三甲基苯醌中的应用 | |
WO2021109099A1 (zh) | 利用微通道连续流反应器制备 5- 单硝酸异山梨酯的方法 | |
CN101962328B (zh) | 一种制备抗抑郁药氟西汀的方法 | |
CN115286629B (zh) | 一种催化制备医药中间体3-苯氨基咪唑[1,2-a]吡啶衍生物的方法 | |
CN117586111B (zh) | 一种连续催化加氢制备四氢姜黄素的方法 | |
CN113185419B (zh) | 一种盐酸奥布卡因的合成方法 | |
CN108311155A (zh) | 一种催化制备治疗前列腺癌症药物阿帕鲁胺中间体的方法 | |
CN106928118B (zh) | 一种制备西洛多辛中间体的方法 | |
CN109012737A (zh) | 一种抗抑郁药物中间体的催化合成方法 | |
CN1311185A (zh) | 4-氨基吡啶及衍生物的制备方法 | |
CN115772077B (zh) | 一种由阿拉伯糖醇催化转化制备手性d-甘油酸的方法 | |
CN108516938B (zh) | 一种制备治疗骨关节炎药物中间体6-羰基己酸甲酯的方法 | |
CN107162933A (zh) | 一种合成阿戈美拉汀重要中间体7‑甲氧基萘乙腈的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Jinghao Inventor after: Zhang Yiqiang Inventor after: Gao Rui Inventor after: Wang Bo Inventor after: Liu Jiaqi Inventor before: Zhang Yiqiang Inventor before: Gao Rui Inventor before: Wang Bo Inventor before: Liu Jiaqi |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200901 Address after: 510000 West 613 Huangpu Avenue, Guangzhou, Guangdong Province Applicant after: NO.1 HOSPITAL ATTACHED TO JINAN University Address before: 276200 Huajian home, Mengshan Road, Mengyin County, Linyi, Shandong Applicant before: Zhang Yiqiang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200922 Termination date: 20210402 |